Companion Diagnostics for Oncology Market Size, Share, Growth Analysis, By Product (Product, Services), By Technology (Polymerase chain reaction (PCR), Next‑generation sequencing (NGS)), By Cancer Type, By End Use, By Region - Industry Forecast 2026-2033

Global Companion Diagnostics for Oncology Market size was valued at USD 3.96 Billion in 2024 and is poised to grow from USD 4.47 Billion in 2025 to USD 11.88 Billion by 2033, growing at a CAGR of 13% during the forecast period (2026–2033).

Companion diagnostics for oncology market players should solely focus on R&D to foster innovation and stand out from the competition. The requirement of huge amount of capital to enter this market makes it a difficult one for start-ups and new companies looking to innovate. Companion diagnostics for oncology providers can also emphasize improving the reimbursement scenario for companion diagnostics to maximize their revenue generation potential in the long run. 'F. Hoffmann-La Roche Ltd.', 'QIAGEN', 'Illumina, Inc.', 'Myriad Genetics, Inc.', 'Thermo Fisher Scientific Inc.', 'Foundation Medicine, Inc.', 'Guardant Health, Inc.', 'Agilent Technologies, Inc.', 'Abbott Laboratories', 'Natera, Inc.', 'NeoGenomics Laboratories Inc.', 'Sysmex Corporation', 'bioMérieux SA', 'Leica Biosystems Nussloch GmbH', 'Exact Sciences Corporation', 'ARUP Laboratories', 'Laboratory Corporation of America Holdings (LabCorp)', 'Quest Diagnostics Incorporated', 'Bio-Rad Laboratories Inc.', 'PerkinElmer, Inc.'

Precision medicine technologies are being rapidly developed and supplemented by high investments in medical R&D. Growing demand for personalized cancer therapies to minimize side effects will also boost the demand for companion diagnostics for oncology in the future.

Biomarker Discovery: Companion diagnostics for oncology companies should focus on discovering new biomarkers to expand thier business scope and revenue generation potential. Using advanced genomic and proteomic techniques and technologies, companion diagnostics for oncology companies can leverage biomarker discovery to their advantage and boost market growth in the future.

North America is slated to hold sway over global companion diagnostics for oncology demand outlook across the forecast period. This dominance can be attributed to surging prevalence of different cancers and high investments in oncology research are key factors that allow North America to account for a dominant stance in the global companion diagnostics for oncology marketplace. High availability of grants and subsidies for oncology research are also helping North America to maintain its dominance. The United States and Canada are projected to be the leading markets for companion diagnostics for oncology providers in this region.